Third BiomeBiome Balance Evidence.
Review the evidence behind Biome Balance, including our CTRI-registered clinical trial and real-world T3B Club member outcomes, with the source and limitations of each finding clearly stated.
CTRI-registered, randomised, double-blinded.
Our registered, double-blinded RCT ran for 45 days. The GTB arm raised stool butyrate by 74% and showed significant improvement across digestive, energy, and sleep domains.
CTRI/2025/09/094597
- TypeRandomised, double-blinded RCT
- NRegistered, 45-day protocol
- Result+74% stool butyrate, GTB arm
- LimitsNo placebo arm
The stats, in full.
Members reported an energy shift by week 2.
When your gut lining is inflamed, your body diverts immune resources away from energy production. Members reported feeling the shift by week 2.
9 out of 10 members reported less bloating within 30 days.
GTB™ inhibits TNF-alpha and rebuilds tight junctions. 9 out of 10 members reported visible bloating reduction within 30 days.
Every surveyed member reported they would recommend Biome Balance.
Across every stewardship cohort, every single member said they would recommend Third Biome to someone they care about.
9 in 10 members reported a difference within 30 days.
Across gut comfort, energy, and mental clarity. Because GTB™ bypasses stomach acid and acts directly on gut cells, the timeline is faster than anything they'd tried before.
More of the right molecule. In exactly the right place.
Our CTRI-registered RCT (45 days, double-blinded) showed the GTB arm raised stool butyrate by 74%, the SCFA your colon lining cells run on.
India didn't have a postbiotic brand. We built one, with proprietary technology to prove it.
Third Biome is India's first precision postbiotic ecosystem. FSSAI-approved. Proprietary GTB technology. Clinically designed.
Why the category is different.
| What matters | Thirdbiome GTB™ (Postbiotic) | Regular probiotic |
|---|---|---|
| How it works | Delivers butyrate directly to gut cells, no colonisation needed Direct | Live bacteria must survive, colonise, then produce metabolites Indirect |
| Survives stomach acid? | Microencapsulation shields GTB through the stomach Protected | 60-90% of live bacteria die before reaching the gut Lost |
| Time to results | Days from first dose Faster | Weeks to colonise Slower |
| Consistency | Fixed molecule, fixed dose, predictable mechanism Measurable | Variable, depends on gut flora and bacterial survival Unpredictable |
| Bloating risk | Zero, postbiotics don't ferment No bloat | Bacteria ferment in gut, causing gas Gas risk |
| Refrigeration? | Shelf-stable at room temperature Stable | Often yes, cold chain required Fragile |
| Mechanisms | TNF-alpha + tight junctions + GLP-1 3 pathways | Depends on which strains survive Indirect |
Disclosure: All T3B Club data is self-reported via weekly check-in questionnaires, Urban India cohorts 2025-2026. The clinical RCT (CTRI/2025/09/094597) had no placebo arm. These statements describe ingredient mechanisms and have not been evaluated by a regulatory authority to diagnose, treat, cure, or prevent any disease.